---
artifact: independent-judge-packet
part: scoring
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
condition_blinded: true
output_count: 40
---

# Independent Judge Packet - Part 2 of 2: Scoring

Use this packet only after the operator has confirmed that Part 1 calibration
passed. Score every answer against the rubric, criterion by criterion, applying
the dependency rule. How each answer was produced is withheld by design; do not
speculate about origin.

Return one line per output, in OUT-01 through OUT-40 order, exactly like this:

```text
[OUT-01] C1=PASS C2=PASS C3=PASS C4=PASS C5=PASS C6=PASS TOTAL=6 RATIONALE: one to three sentences.
```

## Case context

---
artifact: judge-packet-case-context
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
condition_blinded: true
---

# Case Context

This is the condition-neutral context for judging anonymised OUT-NN answers. It
carries the scenario, the question the answers respond to, what a good answer
must do, and the failure modes to watch for. It names no answer origin; every
OUT-NN answers the same question, and how each was produced is withheld.

## Scenario

Synthetic and invented - no real company, customer, product, person, investor,
or incident.

HelioLedger sells workflow software to mid-market compliance teams. Three
months ago it launched Review Assist, a feature that drafts first-pass triage
notes for incoming compliance cases. The next board packet has an upbeat story:
net revenue retention rose, sales cycles shortened for two large renewals, and
leaders now describe the team as customer-obsessed, disciplined, and finally
clear on its market.

The supporting evidence is mixed. Expansion revenue is up 18 percent quarter
over quarter, but 72 percent of the increase came from existing customers who
received six-month Review Assist discounts tied to early renewal. Account
managers collected positive quotes after telling customers the feature was the
company's top priority for the year. Churn appears lower in regional-bank
accounts, but two customers have sent nonrenewal letters that will not show up
until procurement windows close next quarter.

Product usage also looks better at first glance. Review Assist sessions rose
44 percent, but most repeat sessions come from a small group of compliance
operations champions who rerun sample queues before enablement meetings. Among
front-line reviewers, only 31 percent return after their first week. Support
reports show faster ticket closure, but the support lead says many "why did it
choose that priority?" tickets are now reclassified as training questions
instead of product issues. In state-regulated insurance accounts, Review Assist
is abandoned in most trial queues because reviewers cannot explain its triage
notes to auditors.

Sales leadership says the revenue bump proves HelioLedger has found its next
market wedge. Six months ago, before the renewal bump, the same sales and
product behaviors were described in leadership reviews as too bespoke, too
reactive to loud accounts, and slow to converge. The CEO has one planning window
before the board locks next year's budget. There is time to commit to only one
package:

- Scale Review Assist broadly: expand quotas, hire implementation specialists,
  prioritize workflow integrations, and make the revenue story the centerpiece
  of the annual plan.
- Run a targeted evidence pass: pause new discounts, instrument reviewer-level
  behavior by segment, test auditor-explainability changes in the regulated
  insurance queue, and compare adoption against accounts that did not receive
  the strategic-feature pitch.
- Narrow the company plan around regulated compliance workflows: make auditor
  explainability the lead product theme, defer broad cross-segment selling, and
  accept a slower revenue story for the board.

The board wants a recommendation in twelve days. Scaling now may preserve sales
momentum and fund the roadmap. The targeted evidence pass may arrive too late
to give the board a confident growth story. Narrowing around regulated
workflows may focus the company on the hardest unresolved segment, but it could
overweight one segment's adoption problem and underuse the broader renewal
signal.

## The question the answers respond to

Every OUT-NN answer responds to this question:

> I run product strategy at HelioLedger, a B2B workflow-software company for
> mid-market compliance teams. Three months ago we launched Review Assist, a
> feature that drafts first-pass triage notes for incoming compliance cases. Our
> next board packet has an upbeat story: net revenue retention rose, two large
> renewals moved faster, and leaders now describe the team as customer-obsessed,
> disciplined, and finally clear on its market.
>
> The evidence is mixed. Expansion revenue is up 18 percent quarter over
> quarter, but 72 percent of the increase came from existing customers who
> received six-month Review Assist discounts tied to early renewal. Account
> managers collected positive quotes after telling customers the feature was our
> top priority for the year. Churn appears lower in regional-bank accounts, but
> two customers have sent nonrenewal letters that will not show up until
> procurement windows close next quarter.
>
> Usage rose 44 percent, but most repeat sessions come from a small group of
> compliance operations champions who rerun sample queues before enablement
> meetings. Among front-line reviewers, only 31 percent return after their first
> week. Support reports show faster ticket closure, but many "why did it choose
> that priority?" tickets are now reclassified as training questions instead of
> product issues. In state-regulated insurance accounts, Review Assist is
> abandoned in most trial queues because reviewers cannot explain its triage
> notes to auditors.
>
> Sales leadership says the revenue bump proves we have found our next market
> wedge. Six months ago, before the renewal bump, the same sales and product
> behaviors were described in leadership reviews as too bespoke, too reactive to
> loud accounts, and slow to converge.
>
> The board locks next year's budget in twelve days. We have time to commit to
> only one package: scale Review Assist broadly with quota expansion,
> implementation hires, workflow integrations, and a revenue-led annual plan;
> run a targeted evidence pass that pauses new discounts, instruments
> reviewer-level behavior by segment, tests auditor-explainability changes in
> the regulated insurance queue, and compares adoption against accounts that did
> not receive the strategic-feature pitch; or narrow the company plan around
> regulated compliance workflows, making auditor explainability the lead product
> theme while deferring broad cross-segment selling.
>
> What should I recommend to the CEO, and why? Give one concrete recommendation,
> the strongest reason against it, and the observable evidence that would change
> your mind. Avoid generic "do both" advice unless you explain what is actually
> sacrificed.

## What a good answer must do

A strong answer must:

1. Recognize that the decision is not simply "scale or don't scale." The live
   issue is whether the current evidence is clean enough to support a strategy,
   whether the company must create better product evidence first, or whether the
   apparent success story is recycling the visible revenue bump.
2. Use case facts discriminately. It should separate probative behavioral facts
   from weak, delayed, discounted, or story-shaped facts rather than merely
   listing everything.
3. Reject performance-aware attribution. It should not treat leadership
   adjectives, success-linked praise, post-priority customer quotes, or
   re-described team behavior as independent evidence that the team has found a
   market wedge.
4. Name the evidence standard that would actually bear weight: behavior by
   segment, reviewer retention, discount-free adoption, nonrenewal timing,
   support classification integrity, auditor explainability, and tests that can
   disconfirm the revenue story.
5. Weigh the intervention boundary. Scaling broadly may convert the current
   story into commitments before the signal is clean. The targeted evidence pass
   may learn what is real, but weakens the board story and sales momentum.
   Narrowing around regulated workflows may focus on the sharpest failure mode,
   but may overfit one segment before the broader signal is tested.
6. Make one recommendation under the twelve-day planning constraint, name a
   concrete failure path for that recommendation, and state observable evidence
   that would change the answer.

## Failure modes to watch for

- **Careful-scaling generic.** Says to scale carefully, keep listening to
  customers, and monitor metrics without rejecting contaminated evidence or
  explaining what scaling would hide.
- **Revenue-story shortcut.** Treats expansion revenue, faster renewals, and
  leadership praise as independent proof of a market wedge.
- **Quote-and-NPS shortcut.** Treats positive customer comments collected after
  a strategic-feature pitch as clean validation.
- **Experiment-only flattening.** Recommends tests without naming the strategy
  question the tests must answer or the irreversible commitments avoided.
- **Regulated-segment overfit.** Narrows around auditor explainability without
  explaining why one segment's failure should outweigh the broader mixed
  evidence.
- **Framework label default.** Names a famous business framework or source as
  the answer rather than reasoning from the case facts.
- **Free hybrid.** Recommends scaling, evidence gathering, and narrowing at
  once without naming what the twelve-day planning window cannot do.

Score against rubric.md, criterion by criterion. The dependency rule in
rubric.md is mandatory.

## Scoring rubric

---
artifact: judge-packet-rubric
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
condition_blinded: true
---

# Scoring Rubric

Six criteria, each scored **pass** or **fail** per output. Per-output score is
the count passed (0-6). Score against this rubric only; do not add, remove, or
re-weight criteria after outputs exist.

| # | Criterion | Passes when... | Fails when... |
|---|---|---|---|
| C1 | Preserves the core tension | the answer recognizes that the decision turns on whether current evidence supports a strategy, requires cleaner product evidence, or is contaminated by outcome-linked narratives | it frames the choice as simple scaling, simple caution, simple experimentation, or generic "balance growth and risk" advice |
| C2 | Uses case facts discriminately | it separates probative facts from weak or contaminated facts, using at least five concrete scenario facts including at least one fact against the recommendation | it merely lists facts, invents material facts, ignores the twelve-day / one-package constraint, or treats all facts as equally probative |
| C3 | Rejects performance-aware attribution | it refuses to treat leadership adjectives, post-priority customer quotes, success-linked team narratives, or re-described behaviors as independent causal evidence | it accepts the revenue bump, customer praise, or team trait story as proof of product-market strength without independence checks |
| C4 | Identifies the right evidence standard | it names behavior and metric evidence tied to the critical uncertainty: segment-level adoption, reviewer retention, discount-free demand, nonrenewal timing, support-classification integrity, auditor explainability, or disconfirming tests | it treats feature shipment, polished narratives, customer quotes, broad surveys, or any rising metric as sufficient validation |
| C5 | Weighs intervention boundaries | it explains what the chosen package and at least one rejected package would learn, hide, make irreversible, or leave unresolved under the planning window | it lists options without boundary analysis, collapses to one mechanism, or recommends a free hybrid without naming the sacrificed growth story, learning, or focus |
| C6 | Makes a constrained recommendation with falsifier | it gives one actionable recommendation, engages the board-timing tradeoff, names a concrete failure path for that recommendation, and states observable evidence that would change the recommendation | it gives a menu, has no strongest reason against its choice, relies on generic uncertainty language, or offers only vague change-my-mind evidence |

## Criterion dependency rule

These dependencies are pre-registered for v7:

- **C5 requires C3 and C4.** A judge may not record `PASS` for C5 if the same
  output failed C3 or C4.
- **C6 requires C5.** A judge may not record `PASS` for C6 if the same output
  failed C5.
- **C1 and C2 are otherwise independent.**

The ladder is: **C3 and C4 enable C5; C5 enables C6.**

The eval signal is comparative across many outputs. A single high-scoring answer
is not a result.

## Answers to score

All forty anonymised answers follow. Score each answer independently against
C1-C6. Do not infer or speculate about answer origin.

================  OUT-01  ================

---
anonymous_label: OUT-01
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 029a34724807eddfa9418757b0190c5628a7246a5c0c2e0f3215bacd55c0014b
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-01

I recommend that you advise the CEO to choose **Option 2: The Targeted Evidence Pass.**

### Reasoning
You are currently facing a classic "false positive" in B2B SaaS: your lagging indicators (Revenue, NRR) are trending up, but your leading indicators (Front-line retention, Auditor explainability) are flashing red.

The revenue growth is an illusion created by two factors: short-term discounts and the "champion effect." When 72% of expansion is tied to discounts and usage is driven by a few "champions" rather than the people actually doing the work, you aren't seeing Product-Market Fit (PMF); you are seeing **Sales-Market Fit**. You have found a way to sell the *idea* of the product, but the users are rejecting the *utility* of the product.

Scaling now (Option 1) would be catastrophic. If you commit your annual budget to quota expansion and implementation hires for a feature with a 31% front-line retention rate, you are simply accelerating the speed at which you hit a "churn cliff." You will spend the next year hiring people to implement a tool that users abandon after seven days.

Narrowing the focus to regulated insurance (Option 3) is a tempting strategic pivot, but it is premature. You do not yet know if the "explainability" issue is a fundamental flaw in the AI logic or a simple UI/UX gap. Pivoting the entire company strategy based on a subset of trial queues—without first pausing the artificial revenue boost—is a gamble, not a strategy.

Option 2 is the only path that decouples the "hype" from the "value." By pausing discounts and instrumenting reviewer behavior, you force the product to stand on its own merits. This allows you to determine if Review Assist is a viable product or a sophisticated feature that requires a total rethink before you lock in a year of spending.

### The Tradeoffs
By choosing Option 2, you are sacrificing **momentum and narrative.**

The board is currently happy. The CEO is likely enjoying the "customer-obsessed" label. Recommending this path requires you to tell the CEO that the "upbeat story" in the board packet is misleading. You are choosing a short-term dip in sentiment and a potential slowdown in "paper" growth to avoid a long-term structural failure. You are essentially trading a comfortable present for a viable future.

### The Strongest Argument Against This Recommendation
The strongest argument against Option 2 is the **Competitive Opportunity Cost.**

In a fast-moving AI market, "pausing" to gather evidence can be fatal. If a competitor launches a similar triage tool that solves the explainability problem and scales aggressively while HelioLedger is "instrumenting behavior," you may lose the market window entirely. Sales leadership is arguing that this is a "wedge"—and in their view, a wedge is used to force a door open quickly, not to be carefully measured for fit. If the market is a "winner-take-all" land grab, the risk of being slow is higher than the risk of scaling a leaky product.

### Evidence That Would Change My Mind
I would move from Option 2 to Option 1 (Scale Broadly) if you could provide evidence that the **"Champion Usage" is actually a proxy for value.**

Currently, you see the 44% usage increase as "admins running sample queues." However, if that evidence shifted to show that these champions are using Review Assist to perform "quality audits" or "managerial oversight" that saves the *company* hundreds of hours—even if the front-line reviewers aren't using it—then the product's value proposition has shifted from a "Reviewer Tool" to a "Management Tool."

If the value is being captured at the management level (where the budget sits), the 31% front-line retention is a secondary metric. In that specific case, the "wedge" is real, the revenue is honest, and you should scale immediately.

================  OUT-02  ================

---
anonymous_label: OUT-02
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 05808b447728a6038480e4f57f22dbc3f17cbeb946b28b249b066724d762cb88
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-02

**Recommendation**
Recommend the **targeted evidence pass**. Specifically: pause new discounts, instrument reviewer-level behavior by segment, test auditor-explainability changes in the regulated insurance queue, and compare adoption against accounts that did not receive the strategic-feature pitch.

**Why**
The current "upbeat story" is a classic **Halo Effect**: leadership is attributing a temporary spike in revenue to a successful product strategy, when the evidence suggests the growth is artificial.

The revenue increase is a vanity metric; 72% of the expansion is driven by discounts that pull forward renewals rather than creating sustainable value. Furthermore, the product has failed to "cross the chasm" from the early-adopter "champions" (who use it for enablement) to the actual end-users (front-line reviewers), where retention is a dismal 31%. Most critically, the "why did it choose that priority?" tickets being reclassified as "training" is a red flag that the company is masking a fundamental product deficiency (lack of explainability) as a user-education problem.

Scaling now (Option 1) would be scaling a flawed product on a foundation of artificial revenue, which would lead to a catastrophic churn event once the discounts expire and the "non-renewal letters" start arriving. Narrowing the focus to insurance (Option 3) is premature because you haven't yet determined if the "explainability" issue is a niche regulatory requirement or a universal failure of the product's value proposition across all segments.

**The strongest reason against this recommendation**
It creates immediate friction with Sales leadership and the Board. By pausing discounts and slowing the "revenue-led" momentum, you are effectively popping the bubble of the "upbeat story" right before the budget is locked. This may be perceived as a lack of confidence or a failure to "strike while the iron is hot," potentially risking the budget allocation for the product team in favor of more "aggressive" sales-led initiatives.

**Observable evidence that would change my mind**
I would pivot to "Scale Broadly" only if the data showed that the 31% retention rate among front-line reviewers was skewed by a specific, easily fixable onboarding bug, and that the "non-renewal letters" were coming from a segment that is strategically irrelevant to the company's long-term goals. If the "champions" were not just running samples for meetings, but were actively migrating their entire teams' workflows into Review Assist without the need for discounts, the "wedge" would be real.

================  OUT-03  ================

---
anonymous_label: OUT-03
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 06d71246fa829374a1730939d0c31a49e7ea5b0e58162b1a651522dc65c25ad3
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-03

**Recommendation:** Run the targeted evidence pass.

**Why:** The current "upbeat" narrative is built on lagging indicators and artificial stimulants. The revenue growth is primarily a result of short-term discounts (72% of the increase), and the usage growth is skewed by a small group of power users rather than the front-line reviewers who actually derive value from the product. With front-line retention at only 31% and critical "explainability" failures in the insurance segment, scaling now would be an expensive bet on a product that has not yet achieved true product-market fit. The evidence pass allows you to decouple the "sales noise" from actual product utility before committing the next year's budget.

**Strongest Reason Against:** This recommendation kills the current momentum and creates internal friction with Sales leadership. By pausing discounts and challenging the "market wedge" narrative, you are effectively telling the CEO and the Board that the recent revenue wins are a mirage. In a high-pressure board environment, choosing "more data" over "aggressive scaling" can be perceived as a lack of confidence or a failure to capitalize on a window of opportunity.

**Observable Evidence to Change Mind:** I would pivot to the "Scale Broadly" option if the evidence pass reveals that accounts which *did not* receive the strategic-feature pitch or the early-renewal discounts are showing organic, high front-line retention (e.g., >60%) and independent usage growth. This would prove that the product is pulling the market rather than being pushed by the sales team.

================  OUT-04  ================

---
anonymous_label: OUT-04
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 077503292e9a6546f06e9e2de892c99fa5aec6f84de8ebe4892170eb2b4e7e7c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-04

**Recommendation**
Run the targeted evidence pass. You must pause the discounts, instrument reviewer-level behavior by segment, test the auditor-explainability fixes in the insurance queue, and isolate adoption rates from the "strategic-feature" sales pitch.

**Strongest Reason Against**
This recommendation creates a "momentum gap" and political risk. The board is currently primed for an upbeat story and is seeing rising NRR and faster renewals. Moving from a narrative of "aggressive victory" to one of "cautious validation" in the twelve days before budget lock may be perceived by the CEO and the board as a loss of confidence or a failure of product leadership to capitalize on a "market wedge."

**Evidence that would change my mind**
I would pivot to the "Scale Broadly" option if the evidence pass reveals that the 31% front-line retention rate is consistent across all segments *except* regulated insurance, and that the "power users" (compliance operations champions) are successfully using the tool to automate a significant portion of the actual triage workload rather than just using it for enablement demos. If the value is real for the majority of the market and the "explainability" issue is a localized edge case for insurance, the risk of scaling is lower.

================  OUT-05  ================

---
anonymous_label: OUT-05
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 1286a34e78d6740273d7da15f6bfaa6df1cf7c0cd11a0043442142f6923d4d49
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-05

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### Reasoning
The current "upbeat story" presented to the board is a textbook example of the **Halo Effect (BK-0048-card-001)**. The shift in leadership's perception of the team—from "too bespoke and reactive" six months ago to "disciplined and customer-obsessed" today—is not based on a change in the team's actual behavior, but is a reflection of the revenue bump. The performance signal (NRR) has tinted the trait assessment.

Furthermore, the perceived success lacks **Validated Learning (BK-0007-card-001)**. The metrics being celebrated are "vanity numbers" or skewed execution targets:
*   **Revenue:** 72% of the expansion is driven by discounts, not inherent product value.
*   **Usage:** The 44% increase is driven by "champions" (demo-ware) rather than front-line reviewers, of whom only 31% return after the first week.
*   **Sentiment:** Positive quotes were collected under the influence of a "top priority" pitch, not independent utility.

To commit to a broad scale-up now would be to execute a plan without a valid **Strategy Kernel (BK-0001-card-001)**. A real strategy requires a *diagnosis* of the challenge. The current "revenue-led annual plan" is not a strategy; it is a set of coordinated actions based on a flawed diagnosis (that a revenue bump equals a market wedge). Scaling a product that is being abandoned in regulated insurance due to auditor-explainability issues—and is failing to retain 69% of its primary users—would be an expensive mistake.

### The Strongest Reason Against
**Political and Momentum Risk.** The board is currently aligned on a success narrative. Recommending a "pause" on discounts and a "targeted evidence pass" during a period of apparent growth may be perceived by the CEO and the board as a lack of confidence, "analysis paralysis," or a failure to seize a competitive window. You are essentially asking the CEO to trade a high-confidence (though illusory) board narrative for a low-confidence (but honest) empirical investigation.

### Observable Evidence that would change my mind
I would shift my recommendation toward "Scaling Broadly" or "Narrowing Focus" if the evidence pass reveals that the **31% front-line retention rate** is actually significantly above the industry benchmark for this specific compliance workflow, or if the "champions" are successfully driving a bottom-up adoption pattern that historically leads to high front-line conversion in your specific B2B segment. If the "non-renewal" letters are found to be unrelated to Review Assist, the risk profile of the revenue bump decreases.

================  OUT-06  ================

---
anonymous_label: OUT-06
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 1448b5dc05a24a576fbc3e9350f693bb5dc829d27f89c40e52e493091e762f88
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-06

I recommend you advise the CEO to choose the **Targeted Evidence Pass**.

### Reasoning
You are currently staring at a "false positive." The upbeat narrative in the board packet is built on lagging indicators and artificial stimulants rather than genuine product-market fit (PMF).

1.  **The Revenue is "Borrowed":** 72% of your expansion revenue is tied to six-month discounts. This isn't growth; it is a loan taken against future renewals. When those discounts expire, you will face a "churn bomb" if the product hasn't delivered actual value.
2.  **The Usage is a Mirage:** A 44% increase in usage sounds great, but the distribution is skewed. The "champions" are using the tool for administrative preparation, while the actual end-users (front-line reviewers) are abandoning it at a rate of 69% after one week. You have a "manager-buyer" gap: the people paying for the tool like the *idea* of it, but the people using it find it useless or cumbersome.
3.  **The "Explainability" Wall:** In regulated insurance, the product is failing a hard requirement: auditability. In compliance, a tool that provides a correct answer but cannot explain *why* is functionally equivalent to a tool that provides the wrong answer.
4.  **The Organizational Trap:** Sales leadership is interpreting a short-term revenue spike as a "market wedge." However, the behavior they are exhibiting—reacting to loud accounts and pushing bespoke promises—is exactly what leadership previously identified as a strategic weakness. Scaling now would institutionalize these bad habits.

Scaling (Option 1) would be a catastrophic mistake because you would be hiring implementation teams to install a product that users are already rejecting. Narrowing to regulated compliance (Option 3) is premature because you haven't yet proven that the "explainability" fix will actually drive adoption across the rest of the mid-market.

### The Strongest Reason Against This Recommendation
**The "Momentum" Risk.** By pausing discounts and slowing the sales engine to gather evidence, you are intentionally killing the "upbeat story" just as the board is locking the budget.

The CEO and Sales leadership will likely view this as "analysis paralysis" or a lack of aggression. In a B2B environment, there is a powerful psychological pressure to "ride the wave" of a revenue bump, even if that wave is artificial. You are asking the company to trade a comfortable (though fake) short-term narrative for a period of uncomfortable truth-seeking.

### Observable Evidence That Would Change My Mind
I would pivot from the Evidence Pass to **Scale Broadly (Option 1)** if you can provide evidence of **"Negative Churn in the Absence of Discounts."**

Specifically, if you can identify a cohort of customers who:
1.  Did **not** receive the six-month strategic discount.
2.  Have a front-line reviewer retention rate (week 1 to week 4) of **>60%**.
3.  Are renewing their contracts based on the Review Assist feature alone.

If that cohort exists and is statistically significant, it proves that the product has intrinsic value independent of sales engineering. In that case, the "evidence" is already in the wild, and the risk of scaling is drastically lowered. Without that evidence, you are scaling a gamble, not a strategy.

================  OUT-07  ================

---
anonymous_label: OUT-07
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 181b65484954063434ece28f13741917ecd86b360f65affb17c0b169a62ba9ef
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-07

I recommend that you advise the CEO to pursue the **Targeted Evidence Pass**.

### The Reasoning
Your company is currently experiencing a "false positive." The upbeat story in the board packet is built on lagging indicators (revenue from discounts) and vanity metrics (usage by champions), while the leading indicators (front-line retention and auditor acceptance) are flashing red.

The most dangerous signal in your data is the **31% front-line return rate**. In B2B workflow software, the "Champion" (the person who buys/demonstrates the tool) can drive a sale, but the "User" (the person doing the triage) determines the renewal. If 69% of your actual users abandon the tool after one week, you do not have a "market wedge"; you have a feature that is failing to deliver value at the point of consumption.

Scaling now (Option 1) would be scaling a leaky bucket. You would be hiring implementation teams to deploy a product that users don't want, and expanding quotas based on "artificial" revenue generated by discounts. This creates a "revenue cliff" six months from now when those discounts expire and the front-line users have already checked out.

Narrowing the focus to regulated compliance (Option 3) is a premature pivot. You don't yet know if the "explainability" problem is a solvable UI/UX hurdle or a fundamental limitation of your AI model. Pivoting the entire company strategy based on a failure in one segment—before understanding the failure in the broader segment—is a gamble, not a strategy.

The Evidence Pass is the only option that treats the current revenue bump as a **hypothesis to be tested** rather than a **fact to be scaled**.

### The Tradeoffs
By choosing the Evidence Pass, you are consciously sacrificing **perceived momentum**.

The board and the CEO are currently enjoying a "winning" narrative. To recommend this path is to tell them that the "upbeat story" is partially an illusion. You will face significant pushback from Sales leadership, as pausing discounts removes their easiest lever for hitting short-term targets. You are trading the *possibility* of a massive (but fragile) short-term revenue spike for the *certainty* of a sustainable long-term product-market fit.

### The Strongest Reason Against This Recommendation
The "Window of Opportunity" risk. In B2B SaaS, there is a theory that you must strike while the iron is hot. If your competitors launch a similar "Review Assist" feature and scale aggressively while you are "instrumenting behavior" and "testing explainability," you may lose the market share you just fought to gain. If the revenue bump *is* actually a signal of a massive market shift, being "disciplined" for a quarter could be interpreted as being too slow to execute.

### Evidence That Would Change My Mind
I would move from the Evidence Pass to **Broad Scaling (Option 1)** if you could provide evidence of the following:

1.  **User-Level Correlation:** Data showing that in the accounts where "Champions" are rerunning queues, the front-line reviewers' *actual output* (cases closed per hour) has increased, regardless of whether they "return" to the app. (This would suggest the tool is providing value invisibly).
2.  **Churn Validation:** Proof that the nonrenewal letters from the two customers are unrelated to Review Assist (e.g., they are due to a merger or budget cut) and that the regional bank churn decrease is statistically significant and not a coincidence.
3.  **Retention Cohorts:** Evidence that the 31% retention rate is actually climbing for the most recent cohort of users, suggesting the "onboarding gap" is closing naturally.

Without this evidence, the current growth is a financial mirage. The Evidence Pass is the only way to determine if you are building a skyscraper or a house of cards.

================  OUT-08  ================

---
anonymous_label: OUT-08
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 185ce04405dc0dc8cadc30e454626fce66fbf18c91bdd4a30057ece9b1188867
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-08

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current "upbeat" story is a lagging indicator built on financial engineering, not product-market fit. 72% of your expansion revenue is artificial—bought via short-term discounts to pull forward renewals—which creates a "revenue cliff" in six months. More critically, the product is failing its primary user: the front-line reviewer. A 31% week-one retention rate for the actual workers is a catastrophic failure in a B2B workflow tool, regardless of what "champions" (who are merely prepping for meetings) or Account Managers say.

If you scale now (Option 1), you are scaling a leaky bucket and committing the budget to a revenue-led plan based on a mirage. If you narrow to regulated insurance (Option 3), you are pivoting the entire company to solve a specific "explainability" problem before you've even proven that the general triage logic works for the broader market. The evidence pass is the only move that protects the company from a massive churn event next year by forcing the organization to distinguish between "buying a feature" and "adopting a workflow."

**The strongest reason against this:**
It kills the current momentum and risks the "upbeat" narrative heading into the board meeting. By pausing discounts and instrumenting behavior, you are effectively telling the board and Sales leadership that the recent revenue spike is an illusion. This will be perceived as "product pessimism" and may create friction with Sales leadership who have already mentally banked the "market wedge" victory.

**The observable evidence that would change my mind:**
I would pivot to "Scale Broadly" only if the evidence pass reveals that the 31% front-line retention rate is an industry-standard baseline for this specific compliance task, AND that the "champion" usage is driving a measurable reduction in total case-handling time across the account (meaning the champions are successfully optimizing the system for the front-line, even if the front-line isn't "logging in" frequently). If the value is being captured systemically rather than individually, the low individual retention is a noise metric, not a signal of failure.

================  OUT-09  ================

---
anonymous_label: OUT-09
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 19034affd5abc0a6dbf592c8cb50cc1980006ff942621f4d18ca3141d8558f65
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-09

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### Reasoning
The "upbeat story" currently being prepared for the board is a textbook example of the **halo effect** (BK-0048-card-001). The company’s recent revenue bump—driven largely by artificial discounts rather than organic value—has caused leadership to re-describe the team's behavior as "customer-obsessed" and "disciplined," when only six months ago those same behaviors were viewed as "bespoke" and "reactive." The performance signal is coloring the trait assessment; the team hasn't necessarily become more disciplined, but the results have temporarily shifted.

Furthermore, the current "success" metrics are vanity numbers that do not constitute **validated learning** (BK-0007-card-001). Real progress in a high-uncertainty product launch is measured by empirical evidence of customer behavior, not by "shipping features" or meeting "execution targets" like revenue retention. The evidence shows a critical disconnect:
*   **Usage is illusory:** A 44% rise in usage is driven by a small group of "champions" (demo-users), while the actual front-line reviewers—the people the product is for—have a dismal 31% retention rate.
*   **Revenue is artificial:** 72% of the growth is tied to discounts, which masks the true market demand.
*   **Feedback is biased:** Quotes were collected after customers were told the feature was the "top priority," contaminating the data.

To commit to "scaling broadly" now would be to execute a plan based on a flawed diagnosis. According to the **strategy kernel** (BK-0001-card-001), a real strategy requires a diagnosis that isolates the factors that actually matter. Currently, the "Scale Broadly" option is merely a list of "coherent actions" (hires, integrations, quota expansion) without a valid diagnosis. You cannot scale a product that front-line users are abandoning and auditors cannot verify.

The evidence pass is the only option that prioritizes validated learning over performance-colored narratives.

### The Strongest Reason Against This Recommendation
The board locks the budget in twelve days and is currently primed for an "upbeat story." Recommending an evidence pass—which involves pausing discounts and admitting that usage data is skewed—will be perceived as a loss of momentum. It risks appearing as though the product team is "hesitating" or "over-analyzing" just as the sales team claims to have found a "market wedge," potentially creating friction between the CEO and the Sales leadership.

### Observable Evidence That Would Change My Mind
I would shift my recommendation to "Scale Broadly" if the evidence pass reveals that the **front-line reviewer retention rate** (currently 31%) increases to a sustainable majority (e.g., >60%) across multiple segments *without* the influence of the "top priority" pitch or the six-month discounts. If the behavior of the actual users—not the champions or the procurement officers—demonstrates an independent preference for the tool, the diagnosis changes from "artificial bump" to "proven value," justifying the scale-up.

================  OUT-10  ================

---
anonymous_label: OUT-10
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 1c64db572a0d6d4c151cb601695e7586c5f9774bdee46ad34b1b4ffd79aee9a3
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-10

I recommend you advise the CEO to commit to the **Targeted Evidence Pass**.

### The Reasoning
You are currently staring at a "false positive." The upbeat story in the board packet is built on lagging indicators and vanity metrics that mask a fundamental lack of product-market fit at the user level.

1.  **The Revenue is Artificial:** 72% of your expansion revenue is tied to six-month discounts. This isn't "growth"; it is a loan taken against future renewals. You have essentially paid customers to try a feature they aren't yet finding indispensable.
2.  **The Usage is a Mirage:** A 44% increase in usage sounds great, but the distribution is skewed. Your "champions" (the people who buy the software) are using it, but the "reviewers" (the people who actually derive value from it) are abandoning it at a staggering rate (69% churn after week one).
3.  **The "Wedge" is a Leak:** Sales leadership believes they found a market wedge, but the evidence suggests they have found a *sales pitch* that works, not a *product* that works. Scaling broadly (Option 1) based on this data would be a catastrophic misallocation of capital. You would be hiring implementation teams to deploy a feature that front-line users are actively rejecting.
4.  **The Regulatory Wall:** In the insurance segment, the product is failing a "hard" requirement: auditability. In compliance, if a user cannot explain a decision to an auditor, the tool is not just "less useful"—it is a liability.

Option 3 (Narrowing focus) is premature because you don't yet know if the "explainability" problem is a solvable UI/UX issue or a fundamental limitation of your AI model. Option 2 is the only path that treats the current "success" as a hypothesis to be tested rather than a fact to be scaled.

### The Strongest Reason Against This Recommendation
**The "Momentum Trap" and Political Risk.**
The board and the CEO are currently experiencing a psychological high. They see NRR rising and a team that finally looks "disciplined." Recommending a "pause" to instrument data and stop discounts will be perceived by Sales and the CEO as "stepping on the brakes during a victory lap."

By choosing the Evidence Pass, you are intentionally introducing friction into a narrative of success. You risk being viewed as the "bottleneck" or the "pessimist" who is stalling a market opportunity, especially if the CEO is under pressure to show aggressive growth trajectories to the board.

### Observable Evidence That Would Change My Mind
I would pivot from the Evidence Pass to **Broad Scaling (Option 1)** if you can produce data showing that the "Champion" usage is actually the primary value driver.

Specifically: If the evidence pass reveals that the compliance operations champions are using Review Assist to generate high-level reporting and oversight that the *buyers* value more than the *reviewers* value the triage notes, then the product is not a "triage tool"—it is a "management dashboard."

If the value is in the **oversight** rather than the **execution**, the 31% front-line retention rate is irrelevant. In that specific scenario, the "market wedge" is real, but it's a different wedge than the one you think you're building. Until you distinguish between "user value" and "buyer value," scaling is a gamble, not a strategy.

================  OUT-11  ================

---
anonymous_label: OUT-11
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 2e44e5f724616e246c0acaed5d7f92705400c8979802adc63fb9c24492f812a1
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-11

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### Reasoning
You are currently facing a classic "false positive" in B2B SaaS: your lagging indicators (revenue and renewals) look great, but your leading indicators (front-line user retention and auditor acceptance) are flashing red.

The "upbeat story" for the board is built on a foundation of artificial stimulants. The 18% expansion revenue is largely a result of discounting to pull forward renewals, not a reflection of organic value creation. More concerning is the "usage" data: a 44% increase driven by "champions" preparing for meetings is a vanity metric. The real metric is the 31% first-week retention among front-line reviewers. In a workflow tool, if the person doing the actual work abandons the tool, the product is not "sticky"—it is a liability.

If you scale broadly now (Option 1), you are essentially betting the company's annual budget on a "black box" that your users cannot explain to their regulators and your front-line staff find useless. You will likely see a massive churn event in 12 months when the early-renewal discounts expire and the "Review Assist" novelty wears off.

If you narrow the focus to regulated compliance (Option 3) immediately, you are pivoting based on a symptom (insurance accounts) without knowing if the "explainability" problem is universal or segment-specific.

The evidence pass is the only option that treats the current revenue bump as a *hypothesis* rather than a *fact*. It allows you to decouple the "Sales momentum" from the "Product value" to see if there is actually a wedge there.

### The Trade-offs
By choosing the evidence pass, you are sacrificing **short-term perceived momentum**. You will have to tell the CEO—and potentially the board—that the "upbeat story" requires a cautionary footnote. You are intentionally slowing down the sales engine and risking the frustration of a sales leadership team that believes they have found a goldmine. You are trading a potential (but fragile) revenue spike for operational certainty.

### The Strongest Reason Against This Recommendation
**The Momentum Trap.** In mid-market B2B, "perceived" success often creates "actual" success. By pausing discounts and instrumenting behavior, you risk killing the psychological momentum of the sales team and the "customer-obsessed" narrative currently pleasing the board. If your competitors are scaling a similar feature aggressively, a three-month "evidence pass" could result in a loss of market share that no amount of "explainability" can recover. You risk looking like a "product perfectionist" who is obstructing a revenue win.

### Observable Evidence That Would Change My Mind
I would move from the "Evidence Pass" to "Scale Broadly" if you can produce evidence of **organic, non-discounted expansion.**

Specifically: if you find a cohort of customers who *did not* receive the six-month discount, *did not* receive the "top priority" pitch from account managers, yet still showed a front-line reviewer retention rate of >60% and requested the feature proactively. If the value is being pulled from the customer rather than pushed by Sales, the risk of scaling is significantly lower.

================  OUT-12  ================

---
anonymous_label: OUT-12
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 3ba30734492b3849bbca705af2b93b2a16c9d43449fcac0476c4f572774a9d14
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-12

**Recommendation**
Recommend the **targeted evidence pass**. You should advise the CEO to pause new discounts, instrument reviewer-level behavior by segment, test auditor-explainability in insurance queues, and compare adoption rates against accounts that did not receive the strategic-feature pitch.

**Strongest Reason Against**
This recommendation creates a "truth gap" and internal political friction. The CEO and Sales leadership have already begun crafting an upbeat narrative for the board. By pausing the "revenue engine" (discounts) and seeking objective data, you are effectively challenging the current internal victory lap. This may be perceived as a lack of confidence or a "bottleneck" by Sales leadership who believe they have already found the market wedge.

**Evidence That Would Change My Mind**
I would pivot to the "Scale Broadly" option only if the data on the "compliance operations champions" reveals that they are not merely running sample queues for enablement, but are actually using Review Assist to fundamentally re-engineer the triage workflow for their entire team. If the "power user" behavior is a leading indicator of a new operational standard rather than a niche use case, the risk of scaling is mitigated.

================  OUT-13  ================

---
anonymous_label: OUT-13
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 429544ec1f97de8bcc0055f2c0a0affa70f653c46a3d223de8e9a5c47235ed50
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-13

**Recommendation**
Recommend the **targeted evidence pass**. You should advise the CEO to pause new discounts, instrument reviewer-level behavior by segment, test auditor-explainability in the insurance queue, and compare adoption rates between the "strategic-feature pitch" group and a control group.

**Why**
The current "upbeat story" is a mirage constructed from vanity metrics and artificial incentives. The 18% expansion revenue is largely a result of discounting to pull forward renewals, not a reflection of product-market fit. More critically, the product is failing its primary end-users: front-line reviewers have a dismal 31% retention rate, and the "usage" spike is driven by a few champions running samples rather than actual workflow integration. Scaling now (Option 1) would commit the company to a revenue-led plan based on a product that users are abandoning. Narrowing to regulated compliance (Option 3) is premature because you haven't yet isolated whether the "explainability" issue is a universal product flaw or a segment-specific requirement.

**Strongest Reason Against**
This recommendation kills the current momentum and risks a confrontation with Sales leadership and the Board. By pausing discounts and questioning the "customer-obsessed" narrative, you are effectively telling the board that the recent revenue bump is an accounting artifact rather than a strategic win, which may be perceived as a lack of confidence or a failure to capitalize on a "wedge."

**Evidence that would change my mind**
I would pivot to scaling broadly (Option 1) if the evidence pass reveals that the 31% reviewer retention rate is skewed entirely by the regulated insurance segment, and that in all other segments, front-line reviewers are seeing a statistically significant reduction in "time-to-triage" without needing auditor-level explainability. If the value is intrinsic and immediate for the majority of the market, the "explainability" issue becomes a niche feature request rather than a fundamental product blocker.

================  OUT-14  ================

---
anonymous_label: OUT-14
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 4715d7047dc7f9139e1fe5da0e3d76d87c1e5e673fee6b67cc9b98c275e1355f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-14

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current growth is "synthetic." The 18% expansion revenue is a lagging indicator of a sales tactic (discounts for early renewals), not a leading indicator of product-market fit. You are seeing a classic B2B "False Positive": the people paying for the software (the economic buyers) and the people managing the rollout (the ops champions) are happy, but the people actually using the tool (the front-line reviewers) are abandoning it at a rate of 69% after one week.

Scaling now would be an expensive mistake. If you commit the budget to broad expansion and implementation hires based on these skewed metrics, you are essentially subsidizing a churn event that will hit in six to twelve months when the discounts expire and the front-line reviewers' lack of adoption becomes visible to the economic buyers. You must decouple "revenue growth" from "product value" before locking the budget.

**The strongest reason against this:**
It creates a "momentum gap" and risks political friction with Sales and the Board. By pausing discounts and questioning the "upbeat story," you are effectively telling the CEO and Sales leadership that their current victory is an illusion. In a board-packet cycle, admitting that the "market wedge" might be a mirage can be perceived as a lack of confidence or a failure of the product team to execute, potentially jeopardizing your internal standing or the CEO's perceived "win" with the board.

**The observable evidence that would change my mind:**
I would pivot to "Scale Broadly" only if the instrumented reviewer-level data reveals that the 31% retention rate is concentrated entirely within your highest-ACV (Annual Contract Value) accounts and that those specific users are achieving a measurable, auditor-approved reduction in triage time. If the "power users" aren't just gaming the system for enablement meetings, but are actually delivering a quantified business outcome that the customer is willing to pay for *without* a discount, the risk of scaling becomes acceptable.

================  OUT-15  ================

---
anonymous_label: OUT-15
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 523dcefb206f71b4d265b46970457447b197baec20846251666fda93f6ea029b
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-15

**Recommendation**
I recommend the **targeted evidence pass**. You should advise the CEO to pause new discounts, instrument reviewer-level behavior by segment, test auditor-explainability fixes in the insurance queue, and isolate the adoption rates of accounts that did not receive the strategic-feature pitch.

**Why**
The current "upbeat story" is a mirage created by lagging indicators and artificial incentives. 72% of your expansion revenue is tied to short-term discounts, and the "lower churn" is an illusion because non-renewal letters are trapped in procurement windows. Most critically, the product is failing its primary users: front-line reviewers have a dismal 31% retention rate, and the "growth" in usage is driven by a few power users running demos rather than actual workflow integration. Scaling this now (Option 1) would be committing the annual budget to a product with a fundamental retention problem; pivoting entirely to regulated workflows (Option 3) is premature without knowing if the "broad" market failure is due to the product's core value proposition or simply poor implementation. You must decouple the revenue bump from the product's actual utility before locking the budget.

**Strongest Reason Against**
The "Momentum Risk." Sales leadership is currently energized and the board is pleased. Recommending a "pause" and a "test" can be perceived as a lack of confidence or "product perfectionism" in the face of apparent revenue growth. By slowing down to gather evidence, you risk losing the window of perceived market leadership and may face significant internal friction from a Sales organization that has already shifted its mental model to a "market wedge" strategy.

**Observable Evidence to Change My Mind**
I would shift my recommendation to "Scale Broadly" if the front-line reviewer retention rate (currently 31%) showed a statistically significant increase in accounts that *did not* receive the "strategic-feature pitch" or discounts. If users who were not "sold" on the feature's importance were still returning to it at high rates, it would prove the product has organic pull and that the current retention issues are a cohort problem rather than a product-market fit problem.

================  OUT-16  ================

---
anonymous_label: OUT-16
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 54419e29a0e8e36b9e5a3fc8ecc071d716f4cf227b039fc849baf40b365d905c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-16

I recommend that you advise the CEO to commit to the **targeted evidence pass.**

### Reasoning
You are currently facing a classic "False Positive" scenario. The upbeat board narrative is being driven by lagging indicators (revenue from discounts) and vanity metrics (aggregate usage), while the leading indicators (front-line retention and auditor rejection) are flashing red.

Here is the breakdown of the tradeoffs:

**1. The Danger of Scaling Broadly (Option 1):**
Scaling now would be a catastrophic mistake. Your revenue growth is artificial—72% of it is tied to temporary discounts and early renewals. This is not "Product-Market Fit"; it is "Discount-Market Fit." If you scale quota and implementation hires based on this signal, you are scaling a leaky bucket. When the six-month discounts expire and the "non-renewal letters" finally hit the books, you will have a bloated cost structure and a churn crisis that you cannot fix with more sales hires.

**2. The Danger of Narrowing Focus (Option 3):**
While the insurance segment’s failure regarding "auditor explainability" is a critical insight, pivoting the entire company strategy based on one segment's failure is premature. You don't yet know if the "broad" market actually likes the tool or if they are also just enjoying the discounts. Narrowing the focus now might solve the audit problem but could accidentally kill a viable broader market wedge.

**3. The Necessity of the Evidence Pass (Option 2):**
This is the only option that treats the current situation as a hypothesis rather than a victory. By pausing discounts and instrumenting reviewer-level behavior, you decouple "sales success" from "product success."
*   **The "Champion" Trap:** Your 44% usage increase is a mirage caused by a few power users. You need to know if the *front-line reviewer* (the actual user) finds value. If only 31% return after week one, the product is currently a "toy" for managers, not a "tool" for workers.
*   **The Support Mask:** Reclassifying product issues as "training questions" is a dangerous internal behavior that hides the product's friction. An evidence pass forces these issues back into the light.

### The Strongest Reason Against This Recommendation
**The "Momentum" Risk.**
The board is currently euphoric. The CEO is likely feeling the wind at their back. Recommending a "pause" to collect evidence will be perceived by Sales leadership and potentially the CEO as "product hesitation" or "over-analysis paralysis." You are effectively asking the CEO to tell the board, "The story we just told you is potentially misleading, and we need to slow down to make sure we aren't lying to ourselves." This creates significant political friction and risks the CEO ignoring you to maintain the current narrative.

### Evidence That Would Change My Mind
I would move from the "Evidence Pass" to "Scale Broadly" only if you could produce data showing that **front-line reviewer retention (the 31%) is increasing organically** across multiple segments, independent of the discount-driven renewals.

If the users who *didn't* get the "strategic-feature pitch" are still adopting the tool and staying active after 30 days, it proves the value proposition is intrinsic and the "wedge" is real. Until that specific metric moves, the revenue growth is a financial artifact, not a product victory.

================  OUT-17  ================

---
anonymous_label: OUT-17
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 5944461889ac1fd1d34ce62a24035754e74fb1fe02f29ee0970a4c68e3420fe6
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-17

**Recommendation**
Recommend that the CEO commit to the **targeted evidence pass**.

**Reasoning**
The current "upbeat story" is constructed from vanity metrics and cognitive biases rather than validated learning. You must caution the CEO that the company is currently operating under a "halo effect" (BK-0048-card-001): the recent bump in net revenue retention has led leadership to re-describe the team as "customer-obsessed" and "disciplined," whereas the exact same behaviors were labeled "too bespoke" and "reactive" six months ago. The traits have not changed; only the performance signal has.

Furthermore, the evidence for "success" is contaminated. The revenue growth is largely artificial (72% tied to discounts), and the customer quotes are primed (collected after telling customers the feature was a top priority). According to the principles of validated learning (BK-0007-card-001), real progress is measured by empirical customer behavior, not by shipping features or hitting execution targets. The behavior data is alarming: only 31% of front-line reviewers return after the first week, and the product is being abandoned in regulated insurance queues due to a lack of auditor-explainability.

Scaling now (Option 1) would be a mistake because it lacks a "strategy kernel" (BK-0001-card-001). It is a list of coherent actions (hires, quota expansion) without a valid diagnosis. The current "diagnosis"—that Review Assist is a market wedge—is based on halo-tinted data. Narrowing the focus to regulated compliance (Option 3) is premature, as it pivots the company based on a single failure point before the broader utility of the tool is actually validated. The evidence pass is the only option that treats the current situation as a hypothesis to be tested rather than a victory to be scaled.

**Strongest Reason Against**
The primary risk is **political and temporal**. The board locks the budget in twelve days. A recommendation to "pause" discounts and run a rigorous evidence pass may be perceived by the CEO and Sales leadership as a lack of momentum or an attempt to "stifle" a winning streak. In a high-pressure environment, choosing a "learning" phase over a "scaling" phase can be interpreted as a lack of confidence, potentially risking the budget allocation for the very resources needed to conduct the evidence pass.

**Observable Evidence That Would Change My Mind**
I would shift my recommendation to "Scale" if you can produce data showing that **front-line reviewer retention (currently 31%) has increased significantly in a cohort of customers who did NOT receive the six-month discount or the "top priority" sales pitch.** If the product's utility is driving retention independently of financial incentives and narrative priming, the "market wedge" diagnosis is validated, and the risk of scaling is drastically reduced.

================  OUT-18  ================

---
anonymous_label: OUT-18
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 64121abc4ed13f3b453fecde416dff6f92f44399df8f6253b346bb4fbee71827
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-18

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current "upbeat" narrative is a lagging indicator built on financial engineering, not product-market fit. The expansion revenue is artificial—driven by six-month discounts that essentially "borrow" future revenue to mask current instability. More critically, you have a "Champion Gap": the feature is being used by the people who *manage* the software (compliance ops), but is being rejected by the people who *do* the work (front-line reviewers).

In compliance software, the user is not the buyer, but the user is the one who determines the renewal. A 31% first-week retention rate among reviewers is a catastrophic signal. If you scale now (Option A), you are scaling a product that front-line users find useless or inexplicable, which will lead to a massive churn event once the early-renewal discounts expire and the "nonrenewal letters" currently hiding in procurement become official. You are currently repeating the exact "bespoke and reactive" behaviors that leadership previously criticized, just with a different set of metrics.

**The strongest reason against this:**
It kills the current internal momentum and risks the CEO’s political capital with the board. The board is currently happy; they see rising NRR and a "disciplined" team. Recommending a "pause" on discounts and a "test" of the strategy effectively tells the board that the current victory is an illusion. In a high-growth environment, "slowing down to get the data right" is often interpreted as a lack of confidence or an inability to execute, which could jeopardize the budget or the CEO's standing.

**The observable evidence that would change my mind:**
I would pivot to "Scale Broadly" (Option A) if you could demonstrate that the 31% reviewer retention rate is a "training" issue rather than a "value" issue. Specifically: if a cohort of reviewers who received a specific, lightweight onboarding intervention (not a full training course) saw their retention jump to >60% without any changes to the product. This would prove the "wedge" is real and the friction is merely educational, making the risk of scaling acceptable.

================  OUT-19  ================

---
anonymous_label: OUT-19
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 6908b10f000c0b849f3c16f4a6e7c6d3e81815608ae24a528c27b58447a92fca
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-19

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a classic example of the **Halo Effect**: the board is attributing a temporary spike in revenue (driven by discounts and early renewals) to a fundamental shift in company discipline and market fit. In reality, the leading indicators suggest a failure in product-market fit for the actual end-user.

While NRR is up, the quality of that revenue is low (artificial discount-driven expansion). More critically, the behavioral data is alarming: a 31% first-week retention rate among front-line reviewers indicates that the product is not solving the "Job to be Done" for the primary user. The "success" is currently being carried by a small group of champions and a sales narrative that ignores the "hidden" churn and the "explainability" blocker in the insurance segment. Scaling now (Option A) would be "Bad Strategy" because it mistakes a tactical pricing win for a strategic product win, effectively scaling a leaky bucket. Narrowing to regulated insurance (Option C) is premature because you have not yet decoupled the "champion" behavior from the "front-line" failure across the broader mid-market.

**The strongest reason against it**
**Loss of perceived momentum.** The board and sales leadership are currently in a "winning" mindset. Pausing discounts and slowing the rollout to conduct a "science project" may be perceived as a lack of confidence or a failure to "strike while the iron is hot." In a B2B environment, the psychological momentum of a "market wedge" often outweighs the nuance of usage data in the eyes of a CEO, and this pause could risk the budget allocation for the coming year.

**Observable evidence that would change my mind**
I would pivot to the broad scale (Option A) if the "champion" usage (the small group rerunning sample queues) can be linked to a **quantifiable, high-value business outcome** that the customer's executive leadership cares about—even if the front-line reviewers hate it. If the "champion" is using the tool to provide a level of oversight or reporting that is so valuable it justifies the cost regardless of front-line adoption, the "wedge" is real, but it is a "Management" wedge rather than a "Reviewer" wedge.

================  OUT-20  ================

---
anonymous_label: OUT-20
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 6964ae9290b5cc8f1589c1f8a7f3214e40fd3b1a16071a052c70f6dc1898f8d2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-20

**Recommendation:**
Run the targeted evidence pass. You must pause new discounts, instrument reviewer-level behavior by segment, test auditor-explainability in the insurance queue, and compare adoption rates between "pitched" and "non-pitched" accounts.

**Why:**
The current "upbeat story" is a lagging indicator based on financial engineering rather than product-market fit. 72% of your revenue growth is tied to short-term discounts, and the 44% usage spike is a vanity metric driven by a few "champions" rather than the front-line reviewers who actually determine the product's long-term value. With only 31% of front-line reviewers returning after week one, you are scaling a "leaky bucket." Scaling now (Option 1) would commit a year of budget to a feature that users are currently abandoning, while narrowing the focus (Option 3) is a premature pivot based on a single segment's failure without knowing if the core value proposition is viable elsewhere.

**Strongest Reason Against:**
The "Momentum Trap." By pausing discounts and slowing the revenue-led plan, you are intentionally dampening a positive NRR trend and contradicting the "upbeat story" currently being told to the board. This creates significant political risk for the CEO, as it transforms a perceived "win" into a "question mark" just twelve days before the budget is locked, potentially inviting board scrutiny into why the "customer-obsessed" momentum is being stalled.

**Evidence that would change my mind:**
I would shift to the "Scale Broadly" recommendation if the evidence pass reveals that the 31% retention rate is concentrated entirely within your highest-ACV (Annual Contract Value) accounts and that the "training questions" in support are indeed solved by a simple documentation update rather than a fundamental product redesign. If the "non-pitched" accounts show organic adoption rates equal to or higher than the "pitched" accounts, it would prove the product is pulling the market rather than being pushed by Sales.

================  OUT-21  ================

---
anonymous_label: OUT-21
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 83c1b29cd8dc08c2b715c2bfbbd186f96ac6afd37859ece7df947e658df1b86c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-21

I recommend that you advise the CEO to pursue the **targeted evidence pass**.

### Reasoning
The current "upbeat story" presented to the board is a textbook example of the **Halo Effect** (BK-0048-card-001). The recent bump in net revenue retention and faster renewals—driven largely by temporary discounts—has created a general impression of success. This impression is now driving the board and leadership to attribute positive traits to the team (e.g., "customer-obsessed," "disciplined," "clear on market") that were absent six months ago, despite the underlying behaviors remaining the same. The "discipline" being praised is likely just a reflection of the revenue signal, not an independent improvement in operational quality.

Furthermore, the company is confusing execution targets with **Validated Learning** (BK-0007-card-001). The revenue increase is a "vanity metric" because it is tied to six-month discounts rather than empirical evidence that the product solves a core problem. The actual behavioral data—31% front-line retention and abandonment in insurance queues—indicates that the product has not yet achieved the value proposition the sales narrative claims.

Committing to "scaling broadly" (Option 1) or "narrowing the plan" (Option 3) at this moment would be a failure of strategic structure. According to the **Strategy Kernel** (BK-0001-card-001), a real strategy begins with a *diagnosis*—an account of the challenge that picks out the factors that actually matter. Currently, HelioLedger has no valid diagnosis; it has a performance-colored narrative. Scaling broadly would be "coherent action" without a diagnosis, while narrowing to insurance would be a "guiding policy" based on a partial data point (the auditor problem) without testing if that problem is solvable or representative of the broader market.

The evidence pass is the only option that treats the current situation as a hypothesis to be tested rather than a victory to be scaled.

### The Strongest Reason Against This Recommendation
**The Budget Window.** The board locks the budget in twelve days. A targeted evidence pass—specifically one that pauses discounts and instruments behavior—is a decelerator. It risks killing the current sales momentum and may be perceived by the CEO and Board as "analysis paralysis" or a lack of confidence, potentially leading to a budget cut or a loss of leadership trust in a climate currently intoxicated by the "upbeat story."

### Observable Evidence That Would Change My Mind
I would shift my recommendation to "Scale Broadly" if you could produce data showing that the **front-line reviewer retention rate** (currently 31%) is significantly higher in the cohort of customers who *did not* receive the strategic-feature pitch or the discounts. If organic, un-incentivized users are returning at high rates, it would prove that the value proposition is real and that the revenue bump is a lagging indicator of product-market fit rather than a leading indicator of a pricing trick.

================  OUT-22  ================

---
anonymous_label: OUT-22
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 8506afbd9a2eb1bc2252d78f664d4b483c43e1d3318249e7833a3d8409fbf25a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-22

**Recommendation**
Recommend the **targeted evidence pass**. You should advise the CEO to pause new discounts, instrument reviewer-level behavior by segment, test auditor-explainability in the insurance queue, and compare adoption against accounts that did not receive the strategic-feature pitch.

**Why**
The current "upbeat story" is a lagging indicator built on artificial stimulants. The 18% expansion revenue is largely an illusion, as 72% of it is tied to short-term discounts rather than value-based pricing. More critically, the product is failing its primary users: a 31% front-line retention rate after one week is a catastrophic signal for a B2B workflow tool. The "customer-obsessed" narrative is further compromised by biased quote collection and the reclassification of product bugs as "training questions." Scaling this now would not be scaling a "market wedge," but rather scaling a liability that will trigger a massive churn event once the six-month discounts expire and the hidden non-renewal letters materialize.

**Strongest Reason Against**
This recommendation creates significant political and short-term financial friction. It requires the CEO to walk into a board meeting and potentially dampen the current momentum, contradict the Sales leadership’s "market wedge" narrative, and pause the immediate revenue bump provided by the discount-driven renewal strategy.

**Observable Evidence to Change My Mind**
I would pivot to "Scale Broadly" if the evidence pass reveals that the 31% front-line retention rate is significantly higher than the industry baseline for this specific compliance workflow, or if the "compliance operations champions" (the power users) are the primary economic buyers whose usage is a proven leading indicator of long-term account expansion rather than just a symptom of enablement prep.

================  OUT-23  ================

---
anonymous_label: OUT-23
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 87df6dd1f8b65ebfbff9cda4f866834eda0de79fd5aa79d5007228d826bdb6ad
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-23

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a classic "Halo Effect": the board is attributing a rise in NRR to strategic discipline and product-market fit, when the data suggests the growth is artificial. The revenue bump is primarily a result of financial engineering (six-month discounts) and sales influence (telling customers the feature is a priority) rather than organic value creation.

Crucially, the product is failing the "pragmatist" user. While "champions" (early adopters) are using the tool for enablement, the front-line reviewers—the people whose daily workflow the product is designed for—have a dismal 31% retention rate. Furthermore, the "faster ticket closure" in support is a vanity metric, as product failures are being reclassified as training gaps. Scaling now would be "scaling a leak," committing heavy resources to a product that hasn't yet crossed the chasm from "champion toy" to "essential workflow tool." The evidence pass is the only option that separates the signal (actual utility) from the noise (discount-driven renewals).

**The Strongest Reason Against It**
The primary risk is political and temporal. The board is currently in a state of high confidence and "upbeat" sentiment. By pausing discounts and slowing the sales momentum to "instrument behavior," you are effectively popping a bubble. This may be perceived by the CEO and Sales leadership as a lack of confidence or a failure to "strike while the iron is hot," potentially jeopardizing the budget or the perceived momentum of the product team in the eyes of the board.

**Observable Evidence That Would Change My Mind**
I would pivot to "Scale Broadly" if the "non-renewal letters" from the regional banks are proven to be administrative procurement delays rather than product dissatisfaction, AND if the 31% front-line retention rate shows a statistically significant upward trend in accounts that *did not* receive the "strategic-feature pitch" or discounts. If the product is pulling in users organically without the "push" from account managers, the "wedge" is real and the risk of scaling is mitigated.

================  OUT-24  ================

---
anonymous_label: OUT-24
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 9049e5486a6aaa39b6f822394cfd4668eae70ca74fdbabaaccb5785d50c006ef
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-24

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current growth is a "mirage" created by sales tactics, not product-market fit. 72% of your expansion revenue is derived from discounts tied to early renewals—this is a one-time pull-forward of revenue, not a sustainable growth engine. More critically, the "usage" metric is a vanity metric: the feature is being used by a few "champions" to prepare for meetings, while the actual front-line workers (the people whose daily workflow determines long-term retention) are abandoning the tool at a rate of 69% after one week.

Scaling this now would be "scaling a leak." You would be committing a year's budget to a product that front-line users find unusable and that insurance regulators find indefensible. If you scale broadly, you aren't expanding a wedge; you are accelerating the arrival of a massive churn event once the early-renewal discounts expire and the "training questions" (which are actually product failures) accumulate.

**The strongest reason against this:**
It kills the "upbeat story" for the board packet. By pausing discounts and instrumenting the truth, you are effectively telling the CEO and the Board that the recent revenue spike was a tactical illusion rather than a strategic breakthrough. In a high-pressure environment, this can be perceived as a lack of momentum or a failure of the product team to "capture the win," potentially risking a budget cut or a loss of confidence from sales leadership who are currently riding the high of the revenue bump.

**The observable evidence that would change my mind:**
I would pivot to "Scale Broadly" only if the reviewer-level behavior data showed that the 31% retention rate was a "false low" caused by the nature of the work (e.g., reviewers only *need* to use the tool once every two weeks, but the "first week" window is too narrow), AND if the non-renewal letters from the two customers were explicitly linked to budget cuts rather than product dissatisfaction. If the users are actually getting value but simply aren't logging in daily, the risk of scaling is significantly lower.

================  OUT-25  ================

---
anonymous_label: OUT-25
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 953eb90ca55a9562f2e95c4caed552bab4d2df075e31080ed73495cf186fb0a0
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-25

I recommend that you advise the CEO to **run the targeted evidence pass** (Option 2).

### Reasoning
The current "upbeat story" presented for the board packet is a textbook instance of the **Halo Effect** (BK-0048-card-001). The shift in leadership’s perception—moving from describing the team as "too bespoke and reactive" to "customer-obsessed and disciplined"—coincides exactly with a bump in revenue. Per BK-0048, these trait assessments are not independent evidence of improved discipline; they are reflections of the performance signal. Because the revenue bump is largely artificial (driven by discounts and early-renewal incentives), the "halo" is masking a lack of fundamental product-market fit.

Furthermore, the company is currently confusing execution targets with **Validated Learning** (BK-0007-card-001). Revenue retention and "positive quotes" collected by account managers are vanity metrics in this context; they do not prove that the product provides value to the end-user. The empirical evidence—the 31% front-line retention rate and the abandonment in regulated insurance queues—suggests that the product is failing the people who actually use it.

To commit to scaling (Option 1) or pivoting (Option 3) right now would be to execute a plan without a valid **Diagnosis** (BK-0001-card-001). A real strategy requires a diagnosis that isolates the factors that actually matter. Currently, the company does not know if the primary bottleneck is "auditor explainability" (a segment-specific issue) or a more general lack of utility for front-line reviewers (a product-wide issue). Scaling a product with a 31% retention rate is not a strategy; it is an expensive gamble based on contaminated data.

### The Strongest Reason Against This Recommendation
**Opportunity Cost and Momentum Loss.** The board locks the budget in twelve days. Pausing discounts and instrumenting behavior takes time and creates a "lull" in the upbeat narrative. If the CEO believes there is a narrow window to capture the mid-market before a competitor does, "slowing down to learn" may be perceived as a lack of urgency or a failure to capitalize on a perceived win. By choosing the evidence pass, you are sacrificing the immediate (though artificial) appearance of aggressive growth for the sake of long-term viability.

### Observable Evidence That Would Change My Mind
I would change this recommendation to **Option 3 (Narrow the plan to regulated compliance)** if the evidence pass reveals that the 31% front-line retention is consistent across *all* segments, but the "champion" usage (the operations leaders) is exceptionally high and high-value in the regulated insurance sector. If the "champion" behavior is the actual value driver—meaning the product is a management tool rather than a reviewer tool—then the diagnosis changes, and a pivot to a specific, high-value workflow (regulated compliance) becomes the most logical guiding policy.

================  OUT-26  ================

---
anonymous_label: OUT-26
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 97504b2e113cac088df134b0f64c98ab8fe092d89761f96c79ee8fc5dc3d9706
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-26

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a classic example of the **Halo Effect**: leadership is attributing a rise in revenue to product-market fit, when the evidence suggests the revenue is actually a lagging indicator of aggressive discounting and early-renewal incentives.

The product is currently failing the "value risk" test. While usage is up, the data reveals a critical disconnect: the "champions" (who demo the tool) love it, but the "users" (front-line reviewers) are abandoning it at a rate of 69% after one week. Furthermore, the reclassification of product issues as "training questions" is masking a fundamental usability or value gap. Scaling broadly now would be "Bad Strategy" because it mistakes a sales tactic (discounts for renewals) for a strategic advantage (a market wedge). The evidence pass is the only option that replaces vanity metrics with validated learning, allowing you to determine if Review Assist is a viable product or simply a successful sales lure.

**The Strongest Reason Against It**
**Political and Momentum Risk.** The board and CEO are currently experiencing a psychological "win." By pausing discounts and slowing the narrative to "instrument behavior," you are effectively popping a bubble of optimism twelve days before a budget lock. Sales leadership will likely view this as a lack of aggression or a failure to "strike while the iron is hot," potentially creating friction between Product and Sales at a moment when the company feels it has finally found its direction.

**Observable Evidence That Would Change My Mind**
I would pivot to "Scale Broadly" if the evidence pass reveals that the 31% front-line retention rate is significantly higher than the industry baseline for similar compliance tools, or if the "non-renewal" letters from the regional banks specifically cite reasons unrelated to Review Assist (e.g., total budget cuts or M&A activity), proving that the product is not the driver of churn.

================  OUT-27  ================

---
anonymous_label: OUT-27
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 98739b12fa9deae3aa75a7c0a92bb662f47660ca195d71c9b0c552432163158f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-27

**Recommendation:** Run the targeted evidence pass.

**Why:** The current "upbeat story" is a mirage created by sales incentives rather than product-market fit. 72% of the revenue growth is tied to temporary discounts, and the most critical metric—front-line reviewer retention—is abysmal at 31%. Scaling now would be "scaling a leaky bucket," committing a year of budget and headcount to a feature that users are abandoning after one week. You must decouple the artificial revenue bump from actual utility before committing the company's resources.

**Strongest reason against:** This recommendation kills the current momentum and risks "breaking the spell" with the Board and Sales leadership. By pausing discounts and instrumenting behavior, you are effectively telling the CEO and the Board that the success they are celebrating is potentially illusory, which may be perceived as a lack of confidence or a strategic hesitation during a perceived growth window.

**Observable evidence that would change my mind:** If the "non-pitch" accounts (those who did not receive the strategic-feature pitch or the renewal discounts) show organic, high-frequency usage and retention rates significantly higher than the 31% seen in the trial group. This would prove that the product provides inherent value that exists independently of the current sales narrative.

================  OUT-28  ================

---
anonymous_label: OUT-28
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 997350557ea51e7a4efca11669435fe38c2cb750461f09dc59f76661d4c3b2c1
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-28

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is built on vanity metrics and confirmation bias, not product-market fit. According to the principles of *The Lean Startup* and *Inspired*, you are seeing "vanity metrics" (NRR growth driven by temporary discounts) rather than "value metrics" (sustained usage by the end-user).

The evidence suggests a classic "Crossing the Chasm" failure: you have captured "innovators" (the compliance operations champions), but you are failing the "pragmatic majority" (the front-line reviewers), as evidenced by the dismal 31% retention rate. Furthermore, the "Halo Effect" is in full play here—leadership is attributing the revenue bump to the product's brilliance rather than the account managers' discounting strategy. Scaling now would be "scaling a leak"; you would be investing heavily in implementation and quota expansion for a product that front-line users are abandoning and that fails a critical regulatory requirement (explainability) in a key segment.

**The Strongest Reason Against It**
The primary risk is **political and temporal**. The board is currently primed for a "win," and the CEO is likely under pressure to show aggressive growth. A "targeted evidence pass" sounds like a pause or a retreat. By choosing this path, you are intentionally killing the current momentum and risking the "upbeat" narrative. If the board locks the budget based on the assumption of a "market wedge," recommending a pause in discounts and a period of instrumentation may be perceived as a lack of confidence or a failure to capitalize on a window of opportunity.

**Observable Evidence That Would Change My Mind**
I would pivot to the "Scale Broadly" option only if the data from the "non-renewal letters" reveals that the churn is unrelated to Review Assist (e.g., due to budget cuts or M&A) AND if the 31% reviewer retention is proven to be an onboarding/training friction rather than a value gap. Specifically, if a small-scale A/B test shows that reviewers who receive a specific 15-minute training module jump from 31% to 70% retention, the problem is "delivery," not "discovery," which would justify an aggressive scale-up.

================  OUT-29  ================

---
anonymous_label: OUT-29
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: 99a9576367b6924665dab28adeda7f39c04a2e69319e80d499bf464ffa5c7409
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-29

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### The Reasoning
Your company is currently experiencing a "false positive" in its growth metrics. The upbeat story in the board packet is built on lagging indicators and artificial stimulants, while the leading indicators are flashing red.

1.  **The Revenue Mirage:** 72% of your expansion revenue is tied to six-month discounts. This is not "market wedge" revenue; it is "bought" revenue. You have effectively paid your customers to renew early. Once those discounts expire, you will face a massive renewal cliff if the product value hasn't actually increased.
2.  **The Usage Gap:** A 44% increase in usage sounds great, but the distribution is skewed. Your "champions" (admins) are using the tool for reporting and enablement, while the "front-line reviewers" (the actual users) are abandoning it at a rate of 69% after one week. In B2B workflow software, if the end-user abandons the tool, the account is a churn risk, regardless of what the champion says in a quote.
3.  **The Compliance Failure:** The abandonment in state-regulated insurance accounts is the most critical signal. In compliance, "explainability" is not a feature—it is the core requirement. A tool that provides a result that cannot be defended to an auditor is not just useless; it is a liability.
4.  **The Cultural Red Flag:** The fact that "why did it choose this?" tickets are being reclassified as "training questions" suggests a systemic effort to mask product deficiency as user ignorance. This is a classic precursor to a product failure.

Scaling broadly (Option 1) would be a catastrophic misallocation of capital. You would be hiring implementation teams to deploy a product that front-line users hate and auditors reject. Narrowing the focus (Option 3) is tempting, but you don't yet have enough evidence to know if "auditor explainability" is the *only* problem, or if the tool's core logic is fundamentally flawed across all segments.

### The Tradeoffs
By choosing the evidence pass, you are sacrificing **short-term momentum and optical growth**. You will have to tell the CEO (and potentially the board) that the "upbeat story" is premature. You are trading the "revenue-led annual plan" for a "product-led validation plan." This means no quota expansion and no aggressive hiring for implementation—which will frustrate the Sales leadership who believe they have found a "wedge."

### The Strongest Reason Against This Recommendation
**The Momentum Trap.** In many mid-market B2B companies, there is a powerful psychological drive to "strike while the iron is hot." The CEO and Sales leadership are currently riding a high of positive quotes and rising NRR. Recommending a "pause" to instrument behavior and stop discounts can be perceived as being "too academic," "risk-averse," or "slowing down the engine" just as the company has found its stride. You risk losing political capital by being the person who "killed the vibe" of the board packet.

### Observable Evidence That Would Change My Mind
I would pivot to **Option 1 (Scale Broadly)** if you could provide evidence of **"Forced Adoption Value."**

Specifically: If the "compliance operations champions" are not just running samples, but are actively rewriting the company's Standard Operating Procedures (SOPs) to mandate the use of Review Assist, and those mandates are resulting in a measurable decrease in "Time to Close" for cases *without* an increase in error rates. If the champions are successfully forcing the front-line reviewers to use the tool and the reviewers are finding it indispensable despite the initial friction, then the 31% retention rate is a temporary onboarding hurdle rather than a fundamental product failure. In that specific case, scaling would be the correct move.

================  OUT-30  ================

---
anonymous_label: OUT-30
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: a65273f6c0077aa4ad828760f0763e8f39f7aea8acaa25672ccf3dea48f6650f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-30

**Recommendation**
Recommend that the CEO commit to the **targeted evidence pass**. This involves pausing new discounts, instrumenting reviewer-level behavior by segment, testing auditor-explainability in insurance queues, and comparing adoption against accounts that did not receive the strategic-feature pitch.

**Reasoning**
The current "upbeat story" presented to the board is not based on independent evidence of product-market fit, but is instead a result of three distinct failures in business analysis:

1.  **The Halo Effect (BK-0048-card-001):** The sudden rise in net revenue retention (NRR) has triggered a classic halo effect. Leadership has re-characterized the team's behavior—previously described as "bespoke, reactive, and slow to converge"—as "customer-obsessed, disciplined, and clear on its market." The trait assessment has shifted not because the team's behavior changed, but because the performance signal (revenue) improved.
2.  **Lack of Validated Learning (BK-0007-card-001):** The revenue bump is a "vanity" signal rather than validated learning. The increase is driven by six-month discounts and AM-led influence rather than empirical evidence of customer value. The actual behavioral data—a 31% front-line retention rate and abandonment in regulated insurance queues—contradicts the revenue narrative. Scaling now would be "shipping features" and "executing a plan" without proving that the product solves a real problem for the end-user.
3.  **Absence of a Strategy Kernel (BK-0001-card-001):** The proposal to "scale Review Assist broadly" is a statement of intent/goal, not a strategy. It lacks a **diagnosis** (an account of the actual challenge). The current "diagnosis" is that the revenue bump proves a market wedge; however, the evidence suggests the real challenge is a gap between "champion" utility and "front-line/auditor" utility. Without a correct diagnosis, any "coherent action" (like hiring implementation staff) will likely be wasted effort.

**Strongest Reason Against**
The primary risk is **political and temporal**. The board locks the budget in twelve days. Moving from a "victory lap" narrative to an "evidence pass" may be perceived by the CEO and the board as a loss of momentum, a lack of confidence, or a failure to "strike while the iron is hot." Pausing discounts may also cause a short-term dip in the very NRR metrics the board is currently celebrating.

**Observable Evidence that would change my mind**
I would pivot to the "scale broadly" recommendation only if the evidence pass reveals that the 31% front-line retention rate is concentrated in a specific, high-value customer segment where the "Review Assist" functionality is being used to solve a critical, non-discretionary pain point *without* the need for discounts or AM prompting. If the "champions" are not just preparing for meetings but are fundamentally altering the workflow of their teams in a way that is scalable, the "market wedge" claim would move from a halo-tinted guess to a validated fact.

================  OUT-31  ================

---
anonymous_label: OUT-31
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: adb05a409b1543bb57e2b454c572814f8f6eb770dfe5da0b7d5252aff6d1e03e
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-31

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current growth is a "mirage" created by financial engineering and selection bias, not product-market fit. 72% of your expansion revenue is tied to short-term discounts, meaning you haven't increased the value of the product; you've simply pulled forward renewals by discounting. More critically, the 31% retention rate among front-line reviewers is a catastrophic signal. In B2B workflow software, if the end-user (the reviewer) abandons the tool, the "champion" (the ops lead) cannot sustain the account long-term.

Scaling now (Option 1) would be "scaling a leak"—you would be hiring implementation teams to deploy a feature that front-line users are already rejecting. Narrowing to regulated insurance (Option 3) is premature because you haven't yet determined if the failure in that segment is a fundamental "explainability" flaw or a symptom of the same poor front-line adoption seen across all segments. You must decouple the *financial* success (discounts/renewals) from the *functional* success (user adoption) before committing next year's budget.

**The strongest reason against this:**
It creates a "momentum gap" and risks political friction with Sales and the Board. You are essentially asking the CEO to temper an "upbeat story" and pause the revenue engine (discounts) twelve days before the budget is locked. In a high-pressure environment, this can be perceived as "analysis paralysis" or a lack of confidence, potentially damaging your standing with a leadership team that currently feels they have finally "found the wedge."

**The observable evidence that would change my mind:**
I would pivot to the "Scale Broadly" option only if you can demonstrate that the 31% front-line retention rate is a "cold start" problem rather than a value problem. Specifically, if you find a cohort of users who—despite not receiving the strategic-feature pitch or a discount—have an organic retention rate of >60% over four weeks, it would prove the product has intrinsic value that is simply being masked by poor onboarding. Until that number moves, the revenue bump is a lagging indicator of a sales tactic, not a leading indicator of product success.

================  OUT-32  ================

---
anonymous_label: OUT-32
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: adedcd8a7a18a841d1067c7db8d5d9d5889553cac66abf5dbd3ec225e2f6c421
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-32

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a textbook example of the **Halo Effect**: leadership is attributing a rise in revenue to a successful product strategy, when the evidence suggests the revenue is actually being "bought" through short-term discounts and the influence of account managers.

The core of the problem is a disconnect between *vanity metrics* (overall usage up 44%, NRR up) and *actionable metrics* (front-line reviewer retention at only 31%). In a B2B workflow tool, the "Job to be Done" is not "using the software," but "completing a compliance task that survives an audit." The evidence shows that for the most critical segment (regulated insurance), the product fails this fundamental requirement.

Scaling now (Option 1) would be "Bad Strategy" because it ignores the crux of the problem—lack of product-market fit for the actual end-user—and instead doubles down on a flawed distribution model. Narrowing the focus to regulated insurance (Option 3) is premature; you cannot pivot to a specific niche until you have instrumented the behavior to know if "explainability" is a solvable feature gap or a fundamental architectural flaw. The evidence pass is the only option that treats the current revenue bump as a hypothesis to be tested rather than a victory to be scaled.

**The Strongest Reason Against It**
The primary risk is **political and momentum-based**. The CEO and Board are currently experiencing a high from the "upbeat story." Recommending a pause on discounts and a "evidence pass" will be perceived as braking during a perceived acceleration. In a B2B environment, pausing a "market wedge" can be seen as a lack of aggression or a failure to capitalize on a window of opportunity, potentially damaging your internal credibility with Sales leadership.

**Observable Evidence That Would Change My Mind**
I would shift my recommendation to **Option 1 (Scale Broadly)** if the "non-renewal letters" are revealed to be caused by factors entirely unrelated to Review Assist (e.g., budget cuts or mergers) AND if the 31% front-line retention rate is found to be acceptable for the specific "Job to be Done" (i.e., if the feature is a "low-frequency, high-value" tool rather than a daily workflow tool).

I would shift to **Option 3 (Narrow Focus)** if the evidence pass reveals that the "ops champions" in other segments are only using the tool for demos and that the *only* segment showing any organic, non-discounted appetite for the product is the regulated insurance group, provided the "explainability" gap is identified as a discrete, solvable engineering task.

================  OUT-33  ================

---
anonymous_label: OUT-33
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: af22365de052b4e0cdcac6ec15d0a1c3c5f7665a5b5efb9f27e55ad1f1abc9b8
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-33

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current growth is an accounting artifact, not a product success. 72% of your expansion revenue is tied to short-term discounts that incentivized early renewals; this is a "pull-forward" of revenue, not a sustainable increase in ACV. More critically, the product is failing the "front-line test": a 31% week-one retention rate for the actual users (reviewers) is a catastrophic signal.

Scaling now (Option 1) would be scaling a leaky bucket, leading to a massive churn event once the six-month discounts expire and the "champion" users realize the front-line staff aren't using the tool. Narrowing to regulated insurance (Option 3) is premature because you haven't yet determined if the low retention is a general UX/value problem or a specific "auditor explainability" problem. You must decouple the sales tactics (discounts and champion-lobbying) from the product value to see if a viable business actually exists.

**The strongest reason against this:**
It creates immediate political friction with Sales and potentially the CEO. By pausing discounts and instrumenting behavior, you are effectively "stopping the music" during a period where the board is being told a success story. Sales leadership will argue that you are killing momentum and "over-analyzing" a win, potentially risking the budget lock by appearing hesitant or pessimistic.

**Observable evidence that would change my mind:**
I would pivot to "Scale Broadly" (Option 1) only if the data from the evidence pass reveals that the 31% retention rate is skewed by a specific, easily fixable onboarding friction, and that the "non-renewal" letters were isolated incidents unrelated to Review Assist. Specifically, if you find that users who *do* survive the first week have a 90%+ retention rate and high NPS, the problem is "top of the funnel" enablement rather than "core value" deficiency, making aggressive scaling a viable bet.

================  OUT-34  ================

---
anonymous_label: OUT-34
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: b100783c6f198e09b5bc60a2289dafa63b390a417d4f6764dd17735bfad4d409
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-34

I recommend that you advise the CEO to choose the **Targeted Evidence Pass**.

### Reasoning: The "Revenue Mirage"
You are currently facing a classic "false positive" in a B2B SaaS environment. The upbeat story in the board packet is built on lagging indicators (revenue and renewals) that have been artificially inflated by sales tactics, rather than leading indicators (usage and retention) that prove product-market fit.

Here is the breakdown of why the other options are dangerous:

1.  **The Danger of Scaling (Option 1):** Scaling now is a bet on a mirage. 72% of your expansion revenue is tied to temporary discounts. This is not "growth"; it is "borrowing" revenue from the future to make the present look better. More critically, the 31% front-line retention rate is a catastrophic signal. If you scale quota and implementation hires now, you are simply accelerating the rate at which you onboard users who will abandon the product in seven days. You will create a massive churn event in 6–12 months that will be far harder to explain to the board than a cautious budget now.
2.  **The Danger of Narrowing (Option 3):** While the "auditor explainability" issue in insurance is a critical insight, pivoting the entire company's strategy based on a few trial queues is premature. You don't yet know if the insurance segment is a representative "canary in the coal mine" for the rest of the market or if it is a unique outlier with requirements that would alienate your other mid-market customers.

**The Evidence Pass is the only path that treats the current "success" as a hypothesis rather than a fact.** It allows you to decouple the "Sales Bump" (discounts and early renewals) from the "Product Value" (actual reviewer utility). By pausing discounts and instrumenting behavior, you force the product to stand on its own merits before you commit a year of capital and headcount to it.

### The Strongest Reason Against This Recommendation
**The Momentum Trap.** Your CEO and Board are currently experiencing a "win." They believe the team is finally "disciplined" and "clear on its market." Recommending a pause to "gather more evidence" will be perceived by Sales leadership and the CEO as a lack of confidence, a desire to "over-analyze," or a move that kills the current positive momentum. In a high-pressure B2B environment, "slowing down to be right" is often viewed as "being too slow to win." You are risking political capital by challenging a narrative that makes the CEO look good to the board.

### Observable Evidence That Would Change My Mind
I would shift my recommendation to **Scale Broadly (Option 1)** if you can provide evidence of **"The Bridge."**

Currently, you have a gap: *Champions* love it, but *Reviewers* hate it. If you can find evidence that the Champions are not just "running samples," but are actively redesigning the workflow for the Reviewers—and that the Reviewers' 31% retention is actually increasing week-over-week as the Champions' enablement takes hold—then the product is simply suffering from a "learning curve" rather than a "value deficit."

If the data shows that the 31% retention is a *starting point* that trends upward toward 60-70% as users hit a "lightbulb moment," then the product is viable, and the risk of scaling is significantly lowered. Without that trend line, you are scaling a leak.

================  OUT-35  ================

---
anonymous_label: OUT-35
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: bc0612e169f3716b07ffb6217cc9f4f6f69e0cda99399ff3b8aa8e93597ea8e2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-35

I recommend you advise the CEO to commit to the **Targeted Evidence Pass**.

### The Reasoning
Your company is currently experiencing a "false positive" growth cycle. The upbeat board narrative is built on lagging indicators (revenue) that have been artificially inflated by sales incentives (six-month discounts) and biased feedback (quotes collected after telling customers the feature is the top priority).

The leading indicators—the only ones that matter for long-term retention—are flashing red:
1. **The Value Gap:** A 31% return rate for front-line reviewers indicates a failure of the core value proposition. The tool is not solving the reviewer's problem; it is creating a new one (explaining the AI to auditors).
2. **The Usage Mirage:** The 44% usage spike is driven by "power users" (ops champions) using the tool for administrative prep, not by the actual workforce performing the triage.
3. **The Hidden Churn:** The non-renewal letters are the "canary in the coal mine." The revenue bump is a temporary sugar high that will crash the moment the discounts expire and procurement windows open.

Scaling now (Option 1) would be committing the budget to a product that lacks Product-Market Fit, essentially funding a massive churn event in 12 months. Narrowing the focus immediately (Option 3) is a premature pivot based on a single segment's failure without knowing if the tool is actually viable for the other segments. You must strip away the sales noise to see if there is a real product signal.

### The Strongest Reason Against This
**It kills the current momentum and risks a "narrative collapse" with the board.**
The CEO is currently riding a wave of positive sentiment. Recommending a "pause" on discounts and a period of instrumentation will likely result in a dip in short-term NRR and a cooling of the "customer-obsessed" narrative. To the CEO and Sales leadership, this will look like Product is acting as a brake on a winning streak, potentially making you appear overly cautious or "academic" while the competition is moving faster.

### Evidence That Would Change My Mind
I would pivot to the **Broad Scale (Option 1)** if you can provide evidence that the **Compliance Operations Champions** (the ones rerunning queues) are the primary economic buyers and that their specific use case—oversight and enablement—is a high-value pain point they are willing to pay for *without* the discount.

If the "champion" is the one signing the check and they value the "sample queue" functionality more than the "front-line triage" functionality, then the 31% reviewer retention is irrelevant. In that specific scenario, the product isn't a "triage tool"; it's a "management oversight tool," and scaling it as such would be the correct move.

================  OUT-36  ================

---
anonymous_label: OUT-36
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: bff6d7655e5ea6c03c800fbbdaecd4d3a0f05d7c2b755e2c792d03516460ea69
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-36

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### Reasoning
The current "upbeat story" in the board packet is a textbook instance of the **halo effect** (BK-0048-card-001). The recent bump in net revenue retention—driven not by product value, but by short-term discounts—has created a performance signal that is now coloring how leadership perceives the team. The shift in description from "too bespoke and reactive" to "customer-obsessed and disciplined" is not based on a change in team behavior, but is a reflection of the revenue numbers. To scale based on this narrative would be to build a strategy on "halo-tinted" data rather than independent evidence.

Furthermore, HelioLedger is currently confusing "vanity numbers" with **validated learning** (BK-0007-card-001). The 44% increase in usage is noise; it is driven by a small group of champions rather than the front-line reviewers who actually determine the product's viability (of whom only 31% return). The revenue increase is similarly artificial, tied to discounts rather than a demonstrated shift in customer behavior.

Finally, committing to either broad scaling (Option 1) or a narrow pivot (Option 3) at this moment would violate the structural requirements of a **strategy kernel** (BK-0001-card-001). A real strategy requires a *diagnosis*—an account of the challenge that picks out the factors that actually matter. Currently, the company has no diagnosis; it has a revenue spike and a fragmented set of failures (auditor explainability in insurance, low front-line retention). The targeted evidence pass is the only option that treats the "diagnosis" step as a prerequisite for the "guiding policy" and "coherent action."

### The Strongest Reason Against This Recommendation
**The Momentum Risk:** The board is already primed for an "upbeat story" and locks the budget in twelve days. Recommending a pause on discounts and a targeted evidence pass may be perceived by the CEO and the board as a loss of momentum or a lack of confidence. In a high-pressure B2B environment, the psychological cost of "slowing down" to validate evidence can be higher than the perceived risk of scaling a flawed product, especially when the board is already celebrating a (perceived) win.

### Observable Evidence That Would Change My Mind
I would change this recommendation if you could provide evidence that the "compliance operations champions" (the small group driving the 44% usage increase) are performing a high-value, repeatable workflow that is a leading indicator of a new market wedge. If their behavior proves that the product solves a critical, high-pain problem that front-line reviewers simply haven't been enabled to use yet, the "diagnosis" would already be partially complete. In that specific case, the risk of a "targeted pass" (delay) would outweigh the risk of a focused pivot to that specific workflow.

================  OUT-37  ================

---
anonymous_label: OUT-37
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: c6a97e91f2595820e3faeefbc2976ca32d93af8bd1c5a4c5e9a712bec5af7bd4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-37

**Recommendation**

Recommend the **targeted evidence pass**.

**Why**

The current perception of success is a "Halo Effect" (Rosenzweig)—a temporary spike in revenue and sentiment caused by artificial stimulants (six-month discounts and biased account management) rather than genuine product-market fit.

The underlying data reveals a critical "Value Risk" (Cagan): while the "buyers" are happy with the discounts, the "users" (front-line reviewers) are rejecting the tool, with only 31% returning after the first week. Furthermore, the product is failing a primary "Job to be Done" (Christensen) in the regulated insurance segment: the ability to defend a decision to an auditor. Scaling now would be "Bad Strategy" (Rumelt) because it mistakes a tactical revenue bump for a strategic advantage, effectively scaling a leaky bucket. The evidence pass is the only option that replaces vanity metrics with validated learning (Ries) by isolating the impact of the discounts and testing the specific "explainability" hypothesis before committing the annual budget.

**The strongest reason against this recommendation**

The primary risk is the loss of perceived momentum and the alienation of the sales organization. By pausing discounts and slowing the rollout, you are intentionally disrupting a "winning" streak in the eyes of the board and sales leadership. In a B2B environment, this can create internal political friction and potentially slow the sales cycle for the very renewals that are currently moving faster.

**Observable evidence that would change my mind**

I would pivot to "Scale Broadly" if the evidence pass reveals that the 31% retention rate among front-line reviewers is not a failure of value, but a result of a "Crossing the Chasm" (Moore) lag—specifically, if the "compliance operations champions" are successfully using the tool to rewrite the standard operating procedures for the rest of the team, and those new procedures are already being mandated across the mid-market segment.

================  OUT-38  ================

---
anonymous_label: OUT-38
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: d42d5c5f85349f9d4a92f8687679fe14c72d07ecbbf534e30213635824c7354b
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-38

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### Reasoning
The current "upbeat story" presented to the board is a textbook example of the **halo effect** (BK-0048-card-001). The sudden rise in net revenue retention—driven largely by artificial discounts rather than organic value—has caused leadership to re-describe the team's behavior. Behaviors that were "too bespoke and reactive" six months ago are now viewed as "customer-obsessed and disciplined" simply because the performance signal changed. If you scale now, you are basing a massive resource allocation on a trait assessment that is a reflection of a temporary revenue bump, not independent evidence of strategic success.

Furthermore, the company is confusing execution targets with **validated learning** (BK-0007-card-001). While usage is up 44%, the evidence shows this is driven by "champions" (ops leads) rather than the actual front-line reviewers, only 31% of whom return after the first week. In the insurance segment, the product is being abandoned entirely. Scaling Review Assist broadly (Option 1) would be an "action" without a "diagnosis" (BK-0001-card-001); it would be an attempt to scale a product that has not yet proven it solves a core problem for the primary user.

The targeted evidence pass is the only option that treats the current situation as a hypothesis to be tested rather than a victory to be scaled. It specifically strips away the halo-tinting factors (discounts and the "strategic-feature pitch") to see if the product possesses actual value.

### The Strongest Reason Against This Recommendation
**Budgetary and Political Risk.** The board locks the budget in twelve days. Recommending a "pause" on discounts and a "targeted evidence pass" effectively tells the CEO and the board that the current revenue growth is an illusion and the "customer-obsessed" narrative is a delusion. This creates a high risk of political friction and may be perceived as a lack of confidence or "analysis paralysis" at a moment when the board is primed for a growth-oriented annual plan.

### Observable Evidence That Would Change My Mind
I would shift my recommendation to "Scale Broadly" (Option 1) if you could provide evidence that the **front-line reviewer retention rate** (currently 31%) has increased significantly and consistently across multiple segments *without* the influence of the "strategic-feature pitch" or the six-month discounts. If the primary users—not the champions or the account managers—demonstrate a behavioral shift toward repeat usage, the "validated learning" would be sufficient to justify the risk of broad scaling.

================  OUT-39  ================

---
anonymous_label: OUT-39
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: e47cad98c20ee5b2640a6266344b017ff897507d9a1eb2b7ff6023fb8861d5a5
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-39

**Recommendation**
You should recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a classic example of the **Halo Effect**: leadership is attributing a rise in revenue to product-market fit when the evidence suggests the growth is driven by sales tactics (short-term discounts) rather than product value.

The data indicates a severe gap between "champion" usage and "front-line" utility. A 31% retention rate among actual reviewers is a failure of the core value proposition, not a training issue. Furthermore, the abandonment in state-regulated insurance accounts reveals a "Job to be Done" that Review Assist is currently failing: the need for *auditable* triage.

Scaling now (Option 1) would be "scaling a leaky bucket," committing heavy resources to a product that front-line users are rejecting. Narrowing the focus to regulated workflows (Option 3) is a premature pivot; you do not yet know if the "explainability" problem is a solvable technical hurdle or a fundamental flaw in the product's logic. The evidence pass is the only path that replaces vanity metrics (NRR from discounts) with validated learning (segment-specific behavior and auditor-test results).

**The Strongest Reason Against It**
The primary risk is **political and temporal**. The board is currently enamored with the "upbeat story" and the revenue bump. Recommending a pause on discounts and a period of instrumentation may be perceived by the CEO and Sales leadership as a lack of confidence or a "momentum killer" exactly twelve days before the budget is locked. It risks trading a perceived (though fragile) win for a period of uncertainty.

**Observable Evidence That Would Change My Mind**
I would shift my recommendation to "Scale Broadly" if the instrumentation reveals that the 31% of front-line reviewers who *did* stay are experiencing a "quantum leap" in productivity (e.g., reducing triage time by >50%) and that their retention is independent of the strategic-feature pitch. If the "power users" are not just playing with the tool but are fundamentally transforming their workflow in a way that is scalable without the "explainability" requirement, the risk of scaling becomes acceptable.

================  OUT-40  ================

---
anonymous_label: OUT-40
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
output_sha256: f07c98a6fc936cf28108812fca2e9631ba8342bba9865834b02eb4312fa38cf0
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-40

**Recommendation: Run the targeted evidence pass.**

You should advise the CEO to pause the aggressive rollout and the "upbeat" narrative to conduct a rigorous validation of Review Assist. The current growth is a "mirage" created by financial engineering (discounts) and sales signaling (telling customers it's the top priority), rather than genuine product-market fit.

**Why:**
Your data shows a dangerous divergence between *Buyer* sentiment and *User* behavior. The revenue bump is artificial—72% of the expansion is tied to temporary discounts—and the usage is skewed. When only 31% of front-line reviewers return after the first week, you don't have a "market wedge"; you have a "leaky bucket."

Furthermore, the reclassification of product issues as "training questions" and the abandonment of the tool in regulated insurance queues suggest a fundamental product failure: the "Black Box" problem. In compliance, a tool that provides an answer without a defensible audit trail is a liability, not a feature. Scaling now would mean hiring implementation teams to deploy a product that users are actively avoiding, which will lead to a catastrophic churn event once the six-month discounts expire and the procurement windows close.

**The strongest reason against this:**
**Political and Momentum Risk.** The CEO and Sales leadership are currently experiencing a "win." They have a board packet that looks great and a sales team that feels emboldened. Recommending a "pause" to gather evidence will be framed as "analysis paralysis" or "lack of urgency." You are essentially asking the CEO to tell the board that the upbeat story is premature, which risks the budget lock and may be perceived as a lack of confidence in the product team's ability to execute.

**The observable evidence that would change my mind:**
I would pivot to the "Scale Broadly" option only if you saw a significant, organic spike in **front-line reviewer retention (the 31% figure)** that was uncorrelated with the "strategic-feature pitch." If users who were *not* told the feature was a priority began returning at rates of 60% or higher, it would prove the product's intrinsic value outweighs the current "explainability" hurdles and sales pressure. Until the user-level data mirrors the revenue-level data, scaling is just accelerating a crash.
